Cargando…
Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Society of Radiology
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240297/ https://www.ncbi.nlm.nih.gov/pubmed/35695321 http://dx.doi.org/10.3348/kjr.2022.0110 |
| _version_ | 1784737508105388032 |
|---|---|
| author | Finsterer, Josef |
| author_facet | Finsterer, Josef |
| author_sort | Finsterer, Josef |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9240297 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The Korean Society of Radiology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92402972022-07-07 Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible Finsterer, Josef Korean J Radiol Letter to the Editor The Korean Society of Radiology 2022-07 2022-05-31 /pmc/articles/PMC9240297/ /pubmed/35695321 http://dx.doi.org/10.3348/kjr.2022.0110 Text en Copyright © 2022 The Korean Society of Radiology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Finsterer, Josef Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible |
| title | Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible |
| title_full | Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible |
| title_fullStr | Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible |
| title_full_unstemmed | Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible |
| title_short | Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible |
| title_sort | discrimination between benign and malignant post-sars-cov-2 vaccination lymphadenopathy is feasible |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240297/ https://www.ncbi.nlm.nih.gov/pubmed/35695321 http://dx.doi.org/10.3348/kjr.2022.0110 |
| work_keys_str_mv | AT finstererjosef discriminationbetweenbenignandmalignantpostsarscov2vaccinationlymphadenopathyisfeasible |